Savant Capital LLC Reduces Stock Holdings in Exelixis, Inc. $EXEL

Savant Capital LLC trimmed its holdings in Exelixis, Inc. (NASDAQ:EXEL) by 16.2% during the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 121,222 shares of the biotechnology company’s stock after selling 23,484 shares during the quarter. Savant Capital LLC’s holdings in Exelixis were worth $5,006,000 at the end of the most recent reporting period.

Other large investors have also recently made changes to their positions in the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in shares of Exelixis by 81.6% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 43,181 shares of the biotechnology company’s stock worth $1,592,000 after acquiring an additional 19,407 shares in the last quarter. Goldman Sachs Group Inc. raised its stake in Exelixis by 4.9% in the 1st quarter. Goldman Sachs Group Inc. now owns 1,466,779 shares of the biotechnology company’s stock valued at $54,153,000 after purchasing an additional 68,133 shares during the last quarter. Focus Partners Wealth lifted its stake in shares of Exelixis by 83.4% in the first quarter. Focus Partners Wealth now owns 38,458 shares of the biotechnology company’s stock worth $1,420,000 after buying an additional 17,483 shares in the last quarter. Geneos Wealth Management Inc. lifted its stake in Exelixis by 134.3% in the 1st quarter. Geneos Wealth Management Inc. now owns 1,647 shares of the biotechnology company’s stock worth $61,000 after purchasing an additional 944 shares in the last quarter. Finally, Sivia Capital Partners LLC boosted its stake in Exelixis by 23.8% during the second quarter. Sivia Capital Partners LLC now owns 14,362 shares of the biotechnology company’s stock worth $633,000 after buying an additional 2,764 shares during the last quarter. 85.27% of the stock is currently owned by institutional investors and hedge funds.

Exelixis Stock Down 0.7%

Shares of EXEL stock opened at $42.37 on Friday. Exelixis, Inc. has a 52-week low of $32.38 and a 52-week high of $49.62. The stock’s 50-day moving average price is $43.69 and its 200 day moving average price is $41.00. The stock has a market capitalization of $11.36 billion, a PE ratio of 17.88, a price-to-earnings-growth ratio of 0.73 and a beta of 0.42.

Exelixis (NASDAQ:EXEL) last issued its quarterly earnings results on Tuesday, November 4th. The biotechnology company reported $0.78 earnings per share for the quarter, topping the consensus estimate of $0.68 by $0.10. The firm had revenue of $597.76 million during the quarter, compared to the consensus estimate of $590.04 million. Exelixis had a return on equity of 31.06% and a net margin of 29.63%.The company’s revenue for the quarter was up 10.8% on a year-over-year basis. During the same period last year, the company earned $0.47 earnings per share. Analysts expect that Exelixis, Inc. will post 2.04 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, EVP Patrick J. Haley sold 34,187 shares of the firm’s stock in a transaction dated Thursday, November 20th. The shares were sold at an average price of $41.88, for a total value of $1,431,751.56. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Mary C. Beckerle sold 24,622 shares of the business’s stock in a transaction that occurred on Tuesday, November 11th. The stock was sold at an average price of $41.93, for a total value of $1,032,400.46. Following the sale, the director directly owned 21,380 shares in the company, valued at $896,463.40. This trade represents a 53.52% decrease in their position. The SEC filing for this sale provides additional information. In the last quarter, insiders sold 245,235 shares of company stock valued at $10,490,600. Corporate insiders own 2.82% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages have recently issued reports on EXEL. Leerink Partners upgraded shares of Exelixis from a “market perform” rating to an “outperform” rating and set a $48.00 price target for the company in a report on Tuesday, October 21st. Royal Bank Of Canada reiterated a “sector perform” rating and set a $45.00 price target on shares of Exelixis in a research note on Tuesday, October 21st. Barclays upped their price target on Exelixis from $41.00 to $44.00 and gave the stock an “equal weight” rating in a report on Wednesday. Wells Fargo & Company reduced their price objective on shares of Exelixis from $36.00 to $30.00 and set an “equal weight” rating on the stock in a report on Tuesday, October 21st. Finally, HC Wainwright reiterated a “buy” rating and issued a $52.00 price objective on shares of Exelixis in a report on Tuesday. One research analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating, ten have assigned a Hold rating and two have issued a Sell rating to the company’s stock. According to MarketBeat.com, Exelixis has an average rating of “Hold” and an average target price of $46.16.

Key Headlines Impacting Exelixis

Here are the key news stories impacting Exelixis this week:

• Positive Sentiment: Zacks Research upgraded Exelixis from “hold” to “strong‑buy” (2/6), signaling stronger conviction from a well‑known sell‑side source. Zacks.com
• Positive Sentiment: Zacks Research raised multiple quarterly and full‑year EPS estimates across 2025–2027 (examples: FY2026 to ~$2.76 from $2.34 and FY2027 to ~$3.65), improving forward profitability expectations that can justify higher valuation multiple. MarketBeat EXEL Report
• Positive Sentiment: Zacks published bullish commentary on Exelixis’s growth profile and why growth investors should consider the name — coverage that can attract capital from growth‑oriented funds and retail investors. 3 Reasons Why Growth Investors Shouldn’t Overlook Exelixis
• Positive Sentiment: Zacks also flagged Exelixis as a top‑ranked growth stock in its Style Scores coverage, which may increase attention from factor‑based and momentum investors. Top‑Ranked Growth Stock
• Positive Sentiment: HC Wainwright reaffirmed a “Buy” on EXEL, adding another supportive institutional rating that can help sustain demand. HC Wainwright Reaffirms Buy

Exelixis Company Profile

Exelixis, Inc is a biotechnology company specializing in the discovery, development and commercialization of small molecule therapies primarily for the treatment of cancer. Building on a platform that leverages model organism genetics and high-throughput screening, the company focuses its research on kinase inhibitors that modulate critical signaling pathways involved in tumor growth and metastasis. Exelixis’s translational research approach aims to advance novel compounds from early-stage discovery through clinical development and regulatory approval.

The company’s most recognized products include CABOMETYX® (cabozantinib), approved for the treatment of advanced renal cell carcinoma and hepatocellular carcinoma, and COMETRIQ® (cabozantinib) for metastatic medullary thyroid cancer.